Biocryst Pharmaceuticals buy Royal Bank of Canada
Start price
05.11.24
/
50%
€6.61
Target price
05.11.25
€9.16
Performance (%)
14.07%
Price
04.07.25
€7.54
Summary
This prediction is currently active. The prediction currently has a performance of 14.07%. This prediction currently runs until 05.11.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -5.656% | -5.656% |
| iShares Core DAX® | -1.315% | -2.266% |
| iShares Nasdaq 100 | 0.272% | 1.449% |
| iShares Nikkei 225® | -2.496% | 1.560% |
| iShares S&P 500 | 0.504% | 1.340% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.60
30.06.25
30.06.25
€11.09
30.06.26
30.06.26
-0.82%
04.07.25
04.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€8.90
06.05.25
06.05.25
€11.51
06.05.26
06.05.26
-15.26%
04.07.25
04.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.91
11.04.25
11.04.25
€9.75
11.04.26
11.04.26
27.58%
04.07.25
04.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.79
25.02.25
25.02.25
€10.47
25.02.26
25.02.26
-3.18%
04.07.25
04.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.95
25.09.23
25.09.23
€9.44
25.09.24
25.09.24
-2.42%
26.09.24
26.09.24